
Guidance for the 2023/24 financial year
ANNOUNCEMENT NO. 242
13 September 2023
Guidance for the 2023/24 financial year
ChemoMetec has today approved the annual report for 2022/23, including the guidance for 2023/24, which is considered inside information.
For 2023/24, ChemoMetec expects revenue in the range of DKK 400-435 million (2022/23: DKK 442.3 million) and EBITDA in the range of DKK 200-220 (2022/23: DKK 251.0 million).
The annual report for 2022/23, which is released along with this announcement, sets out the underlying assumptions applied in the preparation of the guidance for 2023/24.
Additional information
Rasmus Kofoed, CEO
Tel.: (+45) 26 72 68 19
Niels Høy Nielsen, CFO
Tel.: (+45) 25 51 87 24
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements.
ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.
ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Dutch Court Orders Greenpeace Protesters Off NORI Research Vessel, Greenpeace Complies30.11.2023 18:42:09 CET | Press release
The District Court of Amsterdam has ordered Greenpeace International to immediately disembark from the research vessel commissioned by TMC subsidiary Nauru Ocean Resources Inc (NORI) to conduct legally-mandated environmental impact assessments requested by the Legal and Technical Commission of the International Seabed Authority (ISA) Since November 23rd, Greenpeace’s unsafe and unlawful activities have hindered independent scientists in conducting environmental and scientific studies to assess ecosystem function and recovery one year on from NORI’s pilot nodule collection system testNORI commends Greenpeace’s prompt effort to comply with the court order and looks forward to collaborating to ensure the safety of all personnel at sea NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TMC The Metals Company Inc. (“TMC” or “The Metals Company”), an explorer of lower-impact battery metals from seafloor polymetallic nodules, today announced that the District Court of Amsterdam in the Netherlands ha
Successful completion of recruitment in NANORAD 2, a Phase 2 Clinical Trial of AGuIX® with whole brain radiation therapy in brain metastasis30.11.2023 18:23:37 CET | Press release
Successful completion of recruitment in NANORAD 2, a Phase 2 Clinical Trial of AGuIX® with whole brain radiation therapy in brain metastasis Recruitment led by Grenoble Alpes University Hospital, driven by strong clinical sites participation and investigator support Topline data expected in Q4 2024 Paris (France), November, 30th 2023 – NH TherAguix a Phase 2 biotech company developing AGuIX®, an innovative nanodrug to improve cancer treatment by radiotherapy, announces the completion of recruitment in its NANORAD 2 Phase 2 clinical trial, randomized, multi-center study assessing safety and efficacy of AGuIX® in combination with whole brain radiation therapy versus whole brain radiation therapy alone, in adult patients with multiple brain metastasis. NANORAD 21 is a prospective randomized (1:1) open label trial with a total of 100 patients recruited in 14 active centers coordinated by Dr Camille Verry (CHUGA, Grenoble-Alpes, France) as principal investigator. This trial combines the rad
Vantiva Confirms its Strong Commitment to Diversity, Equity and Inclusion30.11.2023 18:00:00 CET | Press release
Press release Vantiva Confirms its Strong Commitment to Diversity, Equity and Inclusion: the company joins the CEO Action for Diversity & Inclusion™ Initiative; Vantiva has reduced the gender pay gap to 1% as of October 2023. Paris – November 30, 2023 – Vantiva (Euronext Paris: VANTI - formerly known as Technicolor), a global technology leader providing innovative technologies to Network Service Providers (NSPs) that connect consumers around the world, today announced that Chief Executive Officer Luis Martinez-Amago has joined the CEO Action for Diversity & Inclusion™ program, alongside more than 2,400 other business leaders. Signatories of the collective have already shared more than 1,900+ best-known actions, exchanging tangible learning opportunities and creating collaborative conversations via the initiative’s unified hub, CEOAction.com. By participating in this initiative, Vantiva confirms its commitment to taking steps to provide a working environment that respects different view
BW Energy: Mandatory notifications of trade by primary insiders and close associates30.11.2023 17:30:00 CET | Press release
Mandatory notifications of trade by primary insiders and close associates Reference is made to the announcements on 16 November 2023 and 28 November 2023, whereby BW Offshore Limited announced information relating to dividend payments. Please see the attached notifications of trading for information of transactions concerning primary insiders in BW Energy Limited ("BW Energy") and their close associates in connection with the dividend distribution. Further, reference is also made to the announcement on 30 November 2023, whereby it was announced that BW Group Limited purchased 250,000 shares in BW Energy. Please see the attached notification of trading for information of the transaction concerning primary insiders in BW Energy and their close associates in connection with the share purchase of 250,000 shares. For further information, please contact: Knut R. Sæthre, CFO BW Energy +47 91 11 78 76 ir@bwenergy.no About BW Energy: BW Energy is a growth E&P company with a differentiated strat
International Petroleum Corporation Updated Share Capital30.11.2023 17:30:00 CET | Press release
International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) reports the following, in accordance with the Swedish Financial Instruments Trading Act: Following the cancellation of 427,400 common shares repurchased by IPC under the normal course issuer bid / share repurchase program, the total number of issued and outstanding common shares of the Corporation is 128,224,820 common shares with voting rights as at November 30, 2023, and IPC holds no common shares in treasury. International Petroleum Corp. (IPC) is an international oil and gas exploration and production company with a high quality portfolio of assets located in Canada, Malaysia and France, providing a solid foundation for organic and inorganic growth. IPC is a member of the Lundin Group of Companies. IPC is incorporated in Canada and IPC’s shares are listed on the Toronto Stock Exchange (TSX) and the Nasdaq Stockholm exchange under the symbol "IPCO". For further information, please contact: Reb